Anika Therapeutics Jumps 20% on FDA Letter

From BioHealth Investor

Shares of Anika Therapeutics (ANIK) jumped more than 20% on Tuesday after the company announced it had received an approvable letter from the FDA regarding its Cosmetic Tissue Augmentation (CTA) product.

CTA is an injectable filler used for facial wrinkles and other cosmetic procedures. It is based on Anika’s proprietary modified hyaluronic acid, and includes the common anesthetic Lidocaine.

The company expects final approval by end of 2006 and commercialization by mid-2007. The company intends on refiling with the FDA and European Union to enhance product features before commercial launch.

The company’s financials have been looking great as both revenues and net earning have been increasing over the last few years.

The company holds almost $50 million in cash and no debt, and is currently worth less than $150 million on the market.

Shares of Anika closed at $13.90 a share, near its 52-week high of $15.37

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.